Enovis (NYSE:ENOV) Insider Oliver Engert Buys 1,000 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average cost of $23.74 per share, for a total transaction of $23,740.00. Following the completion of the transaction, the insider owned 48,640 shares of the company’s stock, valued at $1,154,713.60. This represents a 2.10% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Oliver Engert also recently made the following trade(s):

• On Monday, March 9th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was purchased at an average cost of $23.39 per share, with a total value of $23,390.00.
• On Friday, March 6th, Oliver Engert acquired 750 shares of Enovis stock. The stock was purchased at an average price of $24.41 per share, with a total value of $18,307.50.
• On Wednesday, March 4th, Oliver Engert acquired 250 shares of Enovis stock. The shares were purchased at an average cost of $25.10 per share, for a total transaction of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were purchased at an average cost of $24.77 per share, for a total transaction of $24,770.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were purchased at an average price of $25.50 per share, for a total transaction of $25,500.00.

Enovis Stock Performance

Shares of NYSE ENOV opened at $23.23 on Tuesday. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -1.12 and a beta of 1.46. Enovis Corporation has a one year low of $21.00 and a one year high of $40.69. The business has a fifty day simple moving average of $23.73 and a 200 day simple moving average of $27.72. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same quarter in the previous year, the company earned $0.98 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Evercore reiterated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Canaccord Genuity Group decreased their price target on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group reissued a “buy” rating and set a $50.00 price objective on shares of Enovis in a report on Monday, January 5th. Finally, Needham & Company LLC boosted their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Hedge Funds Weigh In On Enovis

A number of large investors have recently modified their holdings of the stock. McIlrath & Eck LLC grew its stake in shares of Enovis by 6.9% during the third quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock valued at $167,000 after purchasing an additional 357 shares during the last quarter. Farther Finance Advisors LLC raised its position in Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the last quarter. Amalgamated Bank raised its position in Enovis by 3.6% in the 3rd quarter. Amalgamated Bank now owns 16,793 shares of the company’s stock worth $509,000 after purchasing an additional 585 shares during the last quarter. Heritage Family Offices LLP lifted its holdings in Enovis by 8.9% during the 3rd quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock worth $231,000 after buying an additional 620 shares in the last quarter. Finally, California State Teachers Retirement System lifted its holdings in Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after buying an additional 621 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.